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Dialysis is a lifesaving procedure, or perhaps life prolonging is more appropriate.  The native 
kidneys work 24 hours a day, 7 days a week and filter over 1000 Liters of blood per week.  In addition, to 
concentrating the filtrate (urine), the kidney tubules reabsorb, metabolize, and secrete various 
metabolites.  Thus, kidney failure results in the accumulation of fluid, and accumulation of multiple 
toxins leading to systemic symptom.  Unfortunately, dialysis does not correct the majority of these 
abnormalities.  Typical hemodialysis done thrice weekly only ‘filters’ one tenth of the normal kidney, 
only clears toxins less than 15,000 Daltons, and does not metabolize or synthesize.  In other words, it is 
not a kidney replacement.  The result is systemic derangements in multiple metabolic pathways 
commonly referred to as a “uremic milieu”- an environment that is detrimental to normal physiologic 
processes. 
With the initiation of dialysis, some of these abnormalities are corrected, most notably volume 
overload, but most are not corrected, and many other abnormalities are created.  As noted in this issue 
by Tereshchenko et al
1
, the first few months of dialysis are associated with very high mortality; the 
etiology of which has been thought secondary to the sudden shifts of electrolytes and volume in 
individuals with likely small vessel atherosclerosis or arteriosclerosis.  Once patients survive the first few 
months of undergoing dialysis, the leading cause of death is sudden cardiac death (SCD)- responsible for 
25-35% of all cardiovascular deaths in studies with adjudicated endpoints
2
.   However, the risk of sudden
cardiac death increases with progressive kidney disease even prior to the onset of dialysis such that the 
procedure of dialysis cannot be completely to blame
3
.  Furthermore, the cause of SCD differs from that 
observed in the general population where ventricular rhythms are most commonly observed.   A recent 
study evaluated arrhythmias in 44 patients undergoing hemodialysis through implantable loop recorders 
with continuous cardiac rhythm monitoring.  The most common arrhythmia was bradycardia with 14 
episode of asystole, and only one sustained ventricular tachycardia
4
, results confirmed in our animal 
study
5
.   Thus, patients undergoing dialysis have a unique physiology of SCD that deserves further 
explanation.   
Tereshechenko
1
 argues that toxins released from dialyzers, plastic tubing, and dialysis catheters, 
including polyvinyl chloride (PVC),  bisphenol A (BPA), and Di(2-ethylhexyl) phthalate (DEHP) may be a 
pathogenic cause of sudden cardiac death.  The concept that the dialyzer may be contributing to poor 
outcomes is not new.  The majority of dialyzers used today are made of synthetic polymer blends.  The 
use of synthetic dialyzers began in the 1980s after recognition that cellulose based membranes induced 
acute inflammation
6
.  Bosch-Panadero demonstrated in 2016 that bisphenol A (BPA) is indeed released 
from these ‘new’ synthetic membranes and can also induce inflammation and oxidative stress as did the 
older cellulose based membranes
7
.   Tereschechenko
1
 puts forth the hypothesis of a link between the 
toxins released from plastics and SCD based on in vitro studies demonstrating that DEHP impairs 
electrical conduction in cardiomyocytes.  They further note that hemodialysis, compared to peritoneal 
dialysis, is associated with an increased risk of SCD and argue that the increased plastic exposure with 
hemodialysis may explain the difference in risk.  However, patients receiving peritoneal dialysis, 
compared to hemodialysis, also have preserved residual renal function secondary to the more gentle 
fluid removal and less hypotension with peritoneal dialysis.  This preserved residual renal function is 
associated with preserved metabolic function of the kidney and one study even showed improved left 
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ventricular structure
8
.   Further, no studies to date have associated levels of these toxins with mortality 
or cardiovascular death in dialysis patients.  Thus, the proposed arguments supporting a causative role 
of the plastic metabolites have significant limitations, especially when one considers the uremic milieu 
and the large number of other uremic toxins that have been associated with cardiovascular death.  
However, the lack of convincing data does not negate the need to think twice about adding iatrogenic 
insults to patients with multiple and significant risk factors for SCD.  Unfortunately, we have yet to 
develop a better alternative to dialysis (other than transplant).  Nevertheless, we should at least strive 
to make the procedure as safe as possible.   
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